Low-Dose Hypomethylating Agents for Myelodysplastic Syndromes (MDS)
We aim to provide an overview of the the latest literature on using HMA at low doses in patients with low-risk MDS in this blog post.
We aim to provide an overview of the the latest literature on using HMA at low doses in patients with low-risk MDS in this blog post.